Arbutus Biopharma Corp
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $1.00M | $-0.03 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $179.10M | $0.87 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $500.00K | $-0.04 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $10.70M | $0.01 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | $1.80M | $-0.13 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $1.30M | $-0.10 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jan 13, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Net cash burn | 2025 | $47.00M to $50.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Arbutus Biopharma filed with the SEC
Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Other events · EX-99.1 to Form 8-K
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Agreement terminated · Executive or director change · Other events · EX-99.1 to Form 8-K
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Other events · EX-99.1 to Form 8-K
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
For investor audiences only 19 We believe that both the Moderna COVID - 19 vaccine (SPIKEVAX) and Pfizer/BioNTech
Other events · EX-99.1 to Form 8-K
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
©2025 ARBUTUS BIOPHARMA, INC. Imdusiran RNAi Therapeutic | 8
Results of operations · Other events · EX-99.2 to Form 8-K
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Other events · EX-99.1 to Form 8-K
ARBUTUS PHARMA CORP., et al.,
Other events · EX-99.1 to Form 8-K
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Agreement terminated · Other events · EX-99.1 to Form 8-K
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Other events · EX-99.1 to Form 8-K
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Material agreement · Other events · EX-99.1 to Form 8-K
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Executive or director change · Other events · EX-99.1 to Form 8-K
Arbutus Provides 2025 Corporate and Financial Update
Results of operations · Other events · EX-99.1 to Form 8-K
8 © 20 25 Arbutus Biopharma, Inc. Imdusiran RNAi Therapeutic
Results of operations · Other events · EX-99.2 to Form 8-K
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Other events · EX-99.1 to Form 8-K
8 © 2024 Arbutus Biopharma, Inc. Imdusiran RNAi Therapeutic
Other events · EX-99.3 to Form 8-K
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
8 © 2024 Arbutus Biopharma, Inc. Imdusiran RNAi Therapeutic
Results of operations · Other events · EX-99.2 to Form 8-K
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Other events · EX-99.1 to Form 8-K
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
RNAi Therapeutic 9 © 2024 Arbutus Biopharma, Inc.
Results of operations · Other events · EX-99.2 to Form 8-K
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Other events · EX-99.1 to Form 8-K
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
Other events · EX-99.1 to Form 8-K
Arbutus to Present Imdusiran Data at EASL Congress 2024
Other events · EX-99.1 to Form 8-K
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
RNAi Therapeutic 9 © 2024 Arbutus Biopharma, Inc.
Results of operations · Other events · EX-99.2 to Form 8-K
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Executive or director change · Other events · EX-99.1 to Form 8-K